On Wednesday, Bayer welcomed a decision by the American courts, which ruled in its favor in a dispute concerning its Roundup herbicide, thereby bolstering its share price on the Frankfurt Stock Exchange.

At around 9:45 am, the share price was up 0.4%, having already gained more than 2% the previous day.

In a press release issued last night, the German chemical and pharmaceutical group stated that the San Benito County Court (California) had ruled in its favor, following a lawsuit that had been filed at the beginning of the year.

'The jury's verdict in favor of the company successfully concludes this trial and is consistent with the evidence in the case that Roundup does not cause cancer and is not the cause of the plaintiff's illness', says the group.

Bayer, which claims to have won ten of the last 15 cases involving Roundup, stresses that this victory validates its strategic approach of scientifically proving the absence of danger posed by its weedkiller.

At the time of the publication of its Q3 results, the company had nevertheless recalled that it had set aside provisions of some seven billion euros for its legal expenses, 90% of which related to the glyphosate trials.

According to analysts, this ongoing litigation is a major obstacle to the demerger plans recently mooted by the group, and to the possibility of creating value through an eventual break-up.

With a decline of over 30%, Bayer's share price is the biggest drop in the Euro STOXX 50 index this year, just ahead of Nokia (-29%).

Copyright (c) 2023 CercleFinance.com. All rights reserved.